Oxygenta Pharmaceutical (524636) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
31 Jul, 2026Executive summary
Board approved unaudited financial results for the quarter ended 30 June 2026 and scheduled the AGM for 21 August 2026 via video conferencing.
Appointment of PCR & Associates as Cost Auditors for FY 2026-27 was approved.
Reconstitution of the POSH Committee was completed.
Financial highlights
Revenue from operations for Q1 FY 2026-27 was ₹3,699.69 lakhs, up from ₹1,513.47 lakhs in Q1 FY 2025-26.
Total expenses for the quarter were ₹3,952.75 lakhs, compared to ₹2,343.99 lakhs in the same quarter last year.
Loss before tax for the quarter was ₹250.73 lakhs, an improvement from a loss of ₹814.80 lakhs year-over-year.
Basic and diluted EPS for the quarter were both (₹0.57), compared to (₹1.65) in Q1 FY 2025-26.
Outlook and guidance
The company is actively working to complete identification of MSME creditors and has requested self-declarations from suppliers.
Latest events from Oxygenta Pharmaceutical
- FY26 revenue rose but net loss deepened; board changes and compliance focus highlighted.524636
Q4 25/26 - Revenue rose but net losses widened in Q3 FY26; compliance and creditor processes are ongoing.524636Q3 25/26
- Revenue rose modestly, but losses widened; new CFO appointed and compliance efforts ongoing.524636Q2 25/26
- Q1 FY26 saw higher revenue but a deeper net loss, with new auditor and compliance appointments.524636Q1 25/26
- Q2 FY25 revenue grew and net loss narrowed, with key statutory and compliance actions taken.524636Q2 24/25
- Q1 FY25 revenue up, net loss narrows, equity raised via share allotment; compliance issues persist.524636Q1 24/25
- Revenue surged in FY25, but losses deepened amid compliance and reporting challenges.524636Q4 24/25
- Q3 FY25 revenue surged, but losses deepened and compliance issues remain under review.524636Q3 24/25